Agency Archives - EverGlade

Agency

What the New Executive Order Means for Women's Health Funding

What the New Executive Order Means for Women’s Health Funding

All Posts, ARPA-H, Industry News, Life Sciences / By

Noninvasive, painless methods for diagnosing endometriosis. Wearables to ensure a safer delivery for both mother and baby. Objective biomarkers for chronic pain. These are a few of the projects aimed at improving women’s health that are already receiving federal investment through Advanced Research Projects Agency for Health (ARPA-H). The October 19 Executive Order (EO), Advancing

What the New Executive Order Means for Women’s Health Funding Read More »

DARPA Announces Protein Palace Proposers Day to Advance Universal Protein Purification

All Posts, DARPA, Life Sciences / By

The Defense Advanced Research Projects Agency (DARPA) wants to move protein purification beyond the “one protein, one ligand” model. Its upcoming Protein Palace program aims to develop a universal, tunable platform capable of rapidly purifying virtually any protein with high specificity, purity, and yield. The goal is to overcome a costly, time-consuming bottleneck that limits

DARPA Announces Protein Palace Proposers Day to Advance Universal Protein Purification Read More »

CBRN Medical Countermeasure PBA Opens a Pathway for Therapeutics, Diagnostics, and Development Partners

All Posts, CPE CBRND, Life Sciences / By

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is inviting organizations to join its CBRN Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. The announcement seeks therapeutic developers, diagnostic innovators, and development support organizations to help accelerate the development, testing, and fielding of next-generation medical defense capabilities. The PBA establishes

CBRN Medical Countermeasure PBA Opens a Pathway for Therapeutics, Diagnostics, and Development Partners Read More »

BARDA Seeks SI-Enabled Ultrasound Devices for Point-of-Care Fracture Detection

All Posts, BARDA, Emerging Technologies, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice for Automated Ultrasound-Based, Super Intelligence (SI)-Enabled Fracture Detection. The notice seeks information on commercially available and near-commercial technologies that could support rapid triage of fractures and soft tissue injuries in emergency departments, urgent care centers, and field settings. Responses are due

BARDA Seeks SI-Enabled Ultrasound Devices for Point-of-Care Fracture Detection Read More »

New RFI Seeks Prophylactic Platforms for Medical Countermeasure Development

All Posts, CPE CBRND, Life Sciences / By

The Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense (PME CBRND), through its Accelerated Defense Pharmaceuticals (ADP) program, has issued a Request for Information (RFI) on Prophylactic Platform Technologies for Medical Countermeasures. The government seeks input from commercial and academic product developers with platforms that could accelerate protection against priority chemical, biological, radiological,

New RFI Seeks Prophylactic Platforms for Medical Countermeasure Development Read More »

NSF X-Labs Funding Targets Bioengineering: From Protein Sequence to Function

All Posts, Life Sciences, NSF / By

The National Science Foundation (NSF) has announced From Sequence to Function, a new NSF X-Labs topic supporting platform technologies that connect protein sequence and structure to predictable, controllable biological function. Written proposals are due February 8, 2027, at 5:00 PM Eastern. NSF anticipates one or more Other Transaction (OT) awards under the topic. Issued through

NSF X-Labs Funding Targets Bioengineering: From Protein Sequence to Function Read More »

NIAID Releases 2027 Omnibus BAA for Vaccines, Therapeutics, and Diagnostics

All Posts, Life Sciences, NIAID / By

The National Institute of Allergy and Infectious Diseases (NIAID) has released its 2027 Division of Microbiology and Infectious Diseases (DMID) Omnibus Broad Agency Announcement (BAA) to advance medical interventions for infectious diseases. The solicitation covers three research areas: needle-free vaccines, therapeutic candidates, and in vitro diagnostic platforms. Full proposals for all three areas must be

NIAID Releases 2027 Omnibus BAA for Vaccines, Therapeutics, and Diagnostics Read More »

DARPA Releases Official HUBBLE Solicitation to Map Human Protein Interactions

All Posts, DARPA, Life Sciences / By

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has released the official solicitation for High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators (HUBBLE). The program seeks computational capabilities to map human protein-protein interactions and identify new diagnostic and therapeutic targets for traumatic brain injury (TBI). Required abstracts are due

DARPA Releases Official HUBBLE Solicitation to Map Human Protein Interactions Read More »

Building a Virtual Cell Starts With Better Biological Data

All Posts, DOE, Emerging Technologies, Industry News, Life Sciences / By

On October 7, Biohub, The National Institutes of Health (NIH), and U.S. Department of Energy (DOE) announced a major expansion of an international effort to generate open, AI-ready data for predictive models of biology. The partners describe a $1.8 billion combination of funding, data, computation, and new measurement technology. The long-term goal is a virtual

Building a Virtual Cell Starts With Better Biological Data Read More »

ARPA-H Launches SURPASS to Advance Simulation-Augmented, Real-Time Adaptive Clinical Trials

All Posts, ARPA-H, Emerging Technologies, Life Sciences / By

The Advanced Research Projects Agency for Health’s (ARPA-H) Proactive Health Office has released Innovative Solutions Opening (ISO) ARPA-H SOL 26 164 for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. SURPASS seeks to establish persistent, multi-arm clinical trial platforms that integrate simulation, accumulating human data, prespecified adaptations, shared operational infrastructure, and reusable regulatory assets.

ARPA-H Launches SURPASS to Advance Simulation-Augmented, Real-Time Adaptive Clinical Trials Read More »

BARDA’s “Protection Before Day One” Initiative Seeks Broadly Protective Influenza Vaccines

All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a draft Request for Project Proposals (RPP) for “Protection Before Day One” (PBD1), Solicitation No. RRPV 26-08-PBD1. The initiative seeks to close a central pandemic preparedness gap: the time between identifying a novel pandemic influenza strain and deploying

BARDA’s “Protection Before Day One” Initiative Seeks Broadly Protective Influenza Vaccines Read More »

BioMaP’s REDD Program Outlines a Path to Repurpose Equipment for Drug Delivery

All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA), through its BioMaP Consortium, has outlined a proposed development effort to turn stored manufacturing equipment into a platform for emergency drug delivery. The Repurposing Equipment for Drug Delivery (REDD) draft Statement of Objectives (SOO) calls for a recipient to relocate, restore, and repurpose specialized equipment originally designed to

BioMaP’s REDD Program Outlines a Path to Repurpose Equipment for Drug Delivery Read More »

Scroll to Top